Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026)

Climb Bio's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $5000.0 for Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16000.0 (down 100.01% YoY) and the FY2025 annual result came in at -$21000.0, down 100.02% from the prior year.
• Cash from Financing Activities was $5000.0 for Q1 2026 at Climb Bio, up from -$21000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $128.4 million in Q2 2024 and bottomed at -$21000.0 in Q4 2025.
• A 4-year average of $13.2 million and a median of $32500.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 534908.33% — and 2025, when it tumbled 151.22%.
• Climb Bio's Cash from Financing Activities stood at $288000.0 in 2023, then plunged by 85.76% to $41000.0 in 2024, then tumbled by 151.22% to -$21000.0 in 2025, then jumped by 123.81% to $5000.0 in 2026.
• Business Quant data shows CLYM's Cash from Financing Activities at $5000.0 in Q1 2026, -$21000.0 in Q4 2025, and $41000.0 in Q4 2024.